Maxim Group Upgrades Galmed Pharmaceuticals (GLMD) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Price: $4.63 --0%
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 41
Rating Summary:
5 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 20 | New: 41
Join SI Premium – FREE
Maxim Group analyst Jason McCarthy upgraded Galmed Pharmaceuticals (NASDAQ: GLMD) from Hold to Buy with a price target of $4.00.
For an analyst ratings summary and ratings history on Galmed Pharmaceuticals click here. For more ratings news on Galmed Pharmaceuticals click here.
Shares of Galmed Pharmaceuticals closed at $1.15 yesterday.
You May Also Be Interested In
- Morgan Stanley Upgrades Lockheed Martin (LMT) to Overweight
- Axis Capital Limited Upgrades KEC International Ltd (KECI:IN) to Buy (1)
- ATB Capital Markets Upgrades North American Construction Group (NOA:CN) (NOA) to Outperform (1)
Create E-mail Alert Related Categories
Hot Upgrades, UpgradesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
